Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity

Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity

Synthetic biology can be used to create rationally designed living therapeutics. Here the authors engineer E. coli Nissle to target STING activation in antigen presenting cells for the treatment of solid tumors and demonstrate preclinical activity in murine models.

Bibliographic Details
Main Authors: Daniel S. Leventhal, Anna Sokolovska, Ning Li, Christopher Plescia, Starsha A. Kolodziej, Carey W. Gallant, Rudy Christmas, Jian-Rong Gao, Michael J. James, Andres Abin-Fuentes, Munira Momin, Christopher Bergeron, Adam Fisher, Paul F. Miller, Kip A. West, Jose M. Lora
Format: Article
Language:English
Published: Nature Publishing Group 2020-06-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-020-16602-0

Internet

https://doi.org/10.1038/s41467-020-16602-0

Similar Items